China's Sinovac Biotech says that health officials in Beijing suspended the use of 83 doses of the inactivated hepatitis A vaccine Healive after a minor died two days after being vaccinated. Sinovac noted that out of the 19,850 doses distributed from the same lot of vaccines, no other adverse events had been recorded.
On November 29, regulators inspected Sinovac's manufacturing facility and reviewed its inspections and sales process without finding any irregularities, according to the company. Sinovac says it will continue to cooperate with the authorities and plans a follow-up report.
- check out the Sinovac release
- read RTTNews coverage